Our major discoveries include the following: (1) discovered previously unappreciated oncogenic roles of FBXO6, thus revealing a new role of FBXO6 in the development of ovarian cancer; (2) FBXO6 directly interacted with RNASET2 to target it for ubiquitin-dependent degradation; (3) FBXO6 deficiency stabilized RNASET2 protein to prevent ovarian cancer proliferation, migration, and invasion; (4) FBXO6 was overexpressed in clinical ovarian cancer tissues and high expression of FBXO6 was associated with poor survival of ovarian cancer patients at advanced stages. Here, FBXO6 is linked to ovarian cancer.